California-based CardiAQ Valve Technologies (CVT), a developer of self-conforming and self-anchoring technology for Transcatheter Mitral Valve Implantation (TMVI), has appointed Rob Michiels as chief executive officer (CEO), effective immediately.
Michiels will remain as a director of CVT.
He was president and COO at CoreValve, which was acquired by Medtronic for $700m plus milestone payments in April 2009.
Michiels has also served as CEO of VenPro, general manager/corporate officer of EndoSonics and president/COO of InterVentional Technologies.
He is a founding partner of Consilium, a medical device market research company that is also active in identifying, funding, and greenhousing start-up technologies.
Michiels said as already demonstrated on the aortic side, heart valve therapy will transition to a less-invasive protocol during the coming decade and within that new paradigm, CVT is positioned to offer a percutaneous implantation procedure for the definitive treatment of Mitral Regurgitation.
"While several companies are trying to perfect a percutaneous approach to repair the mitral valve, I feel that these will have a very difficult time demonstrating sufficient efficacy in treating a disease that is very diverse, while CVT’s non-surgical valve implantation approach could become a disruptive technology with a much broader application," Michiels said.